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INTRODUCTION
Metabolic bone disease is under-recognised and under-treated in multiple sclerosis (MS). There is a lack of evidence and guidance for the recognition and treatment of metabolic bone disease, particularly in patients with relapsing-remitting MS (RRMS) who may frequently be exposed to high doses of corticosteroids. Patients with MS (PwMS) have higher rates of fractures than the general population [1] [2] and reduced bone mineral density (BMD) compared to healthy controls [3] . Increasing neurologic impairment as categorised by the Kurtzke Expanded Disability Status Scale (EDSS) [4] is a key factor contributing to osteopenia and osteoporosis in PwMS. [5] [6] [7] However, while poor bone health is common in many chronic neurological diseases, reduced BMD has been identified even in the early stages of MS when patients are fully ambulatory and EDSS is low. [8] High-dose methylprednisolone (intravenous or oral, 3-5g) up to 2-3 times/year is a common treatment for relapses of MS, and is effective in reducing relapse duration. [9] Whilst long-term steroid treatment is a clear risk factor for osteopenia (and osteoporosis) as recognised in the FRAX algorithm; the position is much less clear for pulses of steroid which last for under a week. Short-term corticosteroid therapy has been shown to affect the biochemical markers of bone turnover in PwMS [10] , but the evidence for corticosteroid-induced osteopenia in this group is conflicting. [5, [11] [12] Management of bone health in this population is challenging, as it is difficult to stratify fracture risk.
The WHO FRAX calculator (www.shef.ac.uk/FRAX/) is a tool for predicting risk of fracture, however it has a number of limitations in the setting of MS. It is validated for a general population cohort over the age of 40 [13] , while in a typical relapse clinic the average age is 40 and women are pre-menopausal [14] . Steroids are only included as a risk factor in the FRAX calculation if the dose is at least 5mg/day for more than 3 months, MS is not included as an independent risk factor, and it does not take into account Vitamin D deficiency which is associated with MS [15] and an important modifier of bone health. An alternative, the recent Qfracture tool, includes a wider age range and additional risk factors than the FRAX, [16] however even with this tool the projection of the risk of fracture in this specific population is limited and likely to be an underestimation. [17] Bazelier et al. 4 Murphy et al.
recently described a clinical risk score for the estimation of fracture risk for PwMS which is likely to give a better estimation of fracture risk in this specific population. [18] However this scoring system needs further validation before routine use in a clinical context.
To examine these issues, we wanted to determine the bone status of a sequential cohort of patients attending an acute MS relapse clinic, who received high-dose steroid treatment. We aimed to identify any predictive variables for reduced BMD and create a simple management algorithm to improve quality of clinical care for this patient group.
METHODS
The National Hospital of Neurology and Neurosurgery MS relapse service has been described before, [19] but in brief, PwMS are tele-triaged by an MS-trained healthcare professional and then, if a significant relapse is occurring, proceed to a weekly ambulatory outpatient clinic. After assessment, if clinically indicated, a standard steroid regime of intravenous methylprednisolone 1g/day for 3 days is used along with multi-disciplinary therapy input.
We included 56 consecutive patients from our clinic in this quality improvement study. Following medical assessment, 3 patients were deemed to have symptoms which were not compatible with an acute relapse and were excluded from statistical analysis. Demographic information was recorded for all patients, as well as details of MS type and duration, current medications including calcium/vitamin D supplementation, treatment with corticosteroids in the preceding two years (intravenous or oral form) and both pre-relapse and in-relapse EDSS. Lifestyle variables relevant to bone health were also recorded, including body mass index (BMI), smoking status, alcohol consumption, menopausal status and history of fragility fractures. and sex matched population. 10 subjects failed to attend for scheduled DEXA scans, and comparing this group to the 43 subjects who did attend for DEXA, there were no significant differences in terms of gender, age, MS duration or EDSS.
FRAX scores were calculated using the online WHO FRAX Calculator. [20] For patients under 40 the model calculates the probability of a fracture at age 40 (likely to result in an overestimation of fracture risk in younger subjects).
Comparisons between the groups were made with Student's t test for continuous variables and 
RESULTS
The cohort characteristics are described in Table 1 . The mean age of all subjects was 39.6 years and the majority of patients (66%, 95% C.I. 52 to 80%) were fully ambulatory pre-relapse with an EDSS of <4.0. The maximum pre-relapse EDSS of any subject was 6.5, and the majority (87%, 95% C.I. 78 to 96%) were classified as having relapsing remitting MS (RRMS). In-relapse EDSS was ≥ 4.0 in the majority of subjects (80%, 95% C.I. 68 to 92%), with 21 subjects moving from being fully Table 2 shows the 43 subjects with DEXA results (10 did not attend their appointment). DEXA scans were performed at mean 58 days after corticosteroid treatment. 22 (51%) patients were osteopenic (3 of whom were osteoporotic). Two of the 3 osteoporotic patients were post-menopausal women.
Thirty-one of 50 (62%, 95% C.I. 49 to 75%) patients were vitamin D deficient based on the 50nmol/L cut-off recommended by the United States Endocrine Society. [22] Prevalence of Vitamin D deficiency in our cohort was higher than prevalence in the British population (range 3.2% to 46.6% depending on seasonal variation and cut-offs of either 25nmol/L or 40nmol/L). common in this sequential cohort of about 50 patients assessed following an MS relapse, despite the young average age (majority pre-menopausal) and low levels of pre-relapse disability (66% EDSS <4.0, 95% C.I. 52 to 80%). However statistical analysis failed to reveal any significant differences between those with normal BMD and those with osteopenia in terms of: 25(OH)D levels, relapse frequency or disability level (either pre-relapse or in-relapse EDSS).
It has been difficult to elucidate the reason for reduced bone density in the early stages of MS.
Various studies have shown heterogeneity of predictive variables. Kirbas et al. [27] and Moen et al. [28] suggest that this points to a shared aetiology of MS and osteopenia/osteoporosis. Sioka et al. have suggested that the inflammatory process with relapsing MS may be detrimental to bone status [3] , which is supported in the literature relating to rheumatic disease. [29] This hypothesis is supported by the disproportionately low BMD we have demonstrated in our study of young ambulatory patients with active MS. Finally, the evidence for an epidemiological association between MS and Vitamin D deficiency continues to accrue [30] , and vitamin D levels are an important long-term modifier of bone health. [31] Our study shows that the frequency of steroid course over the preceding 2 years did not influence BMD, and supports other studies demonstrating no detrimental impact of short-term high-dose steroids. [12] Indeed, glucocorticoid-induced osteoporosis is only considered a risk in those patients who receive at least 5mg Prednisolone (or equivalent dose of other glucorticoids) for at least 3 months. [32] However there is increasing evidence that the impact of steroids on bone health extends beyond BMD. Patients on long term steroids experience fractures at a higher BMD than controls [33] and steroids have been shown to have a negative impact on bone modeling and architecture that is not detected in standard DEXA scanning. [34, 35] Further longitudinal studies are required to examine the influence of high-dose corticosteroid use on long-term outcome measures (including fracture rates) in the MS population.
The question arises as to how to assess the bone health of patients attending with an MS relapse, if it had not been previously or recently examined. From this data, one approach would be to measure the Vitamin D and BMD using DEXA of all patients attending with a relapse, since their risk appears to be so high. However, considering the young age of this population and the resource utilisation this would require, we advocate a more conservative approach to identify patients in need further investigation.
Considering the above, we suggest here an algorithm to manage the inter-related issues of 25(OH)D deficiency and reduced BMD (Figure 1 ). Initial assessment includes evaluation of lifestyle factors along with blood tests relevant to bone health, including serum 25(OH)D on a yearly basis. All patients should be advised regarding conservative measures to maintain bone density. 9 Murphy et al.
Vitamin D Deficiency
Patients should be offered Vitamin D supplementation if their serum level is deficient (<50nmol/L). In particular as table 1 shows, less than 20% of this cohort was taking vitamin D/calcium supplements, before the high prevalence of reduced BMD was identified from this study. While 50nmol/L is considered a lower cut-off for Vitamin D deficiency, 70-80 nmol/L should be targetted as the optimal serum level for bone health [37, 38] . To achieve target levels, doses up to 10000 IU per day appear to be safe. [39] We recommend supplementation with Cholecalciferol (Vitamin D3) at a dose of 10000 or 20000 units weekly which should be sufficient to achieve target serum Vitamin D levels. Calcium [41] , however it would seem prudent to monitor calcium levels annually, in case of hypercalcaemia.
DEXA Scanning
Next we consider which patients require formal DEXA scanning. As highlighted by Dobson et al., [40] there is a lack of disease specific evidence or guidelines for the monitoring of bone health in this cohort, but a practical and proactive approach should be employed for early identification of those at increased risk of fractures. DEXA scanning is a non-invasive imaging method with a very low radiation dose (approximately 2.5 microSv). [43] Post-menopausal women are at highest risk of osteoporosis, and we recommend that a DEXA scan is included in initial assessment. For the rest of the patient population (men and pre-menopausal women), we would recommend proceeding to DEXA scan if mobility is impaired (i.e. pre-relapse EDSS ≥ 4.0) or falls risk is high. For patients without these additional risks, we consider the FRAX or QFracture tools to be a useful adjunctive assessment.
We have demonstrated that FRAX scores calculated pre-DEXA imaging have limited predictive value in our study population, and this supports the need for a management approach specific to MS.
However the FRAX and Qfracture tools have been validated in large populations and may certainly have a role in identifying those patients with significant risk factors for reduced BMD independent of MS e.g. comorbid diabetes or rheumatoid arthritis. Management of patients with reduced BMD identified on DEXA scan should be in accordance with local guidelines e.g. the National Osteoporosis Guideline Group in Britain. [44] Timing of DEXA scanning
In our study we carried out DEXA scans at a mean of 58 days after the relapse clinic assessment. This is more practical than completing DEXA imaging in the early acute stage of a relapse, as allowing some time for recovery will likely give a better reflection of long-term BMD. When interpreting DEXA results in this cohort it is also reasonable to assume that regional osteoporosis can occur in the context of a relapse, similar to that described in paretic limbs of stroke patients. [45] Areas of regional paresis should be avoided if possible during DEXA imaging. If regional osteoporosis is demonstrated in a paretic region affected by acute relapse, it may be prudent to delay a treatment decision and repeat DEXA scanning after 6 months to allow a full cycle of bone remodelling.
Strengths and limitations
The strengths of our study include the multi-modal assessment of bone status of patients (lifestyle factors, FRAX assessment, Vitamin D status and BMD), minimal exclusion criteria and our proposal of a clinical algorithm for management of bone health in this population. Our approach is novel as we Murphy et al. chose to focus on a cohort of patients with active disease experiencing MS relapses. The lack of controls and the non-attendance of 10 subjects for DEXA scanning can be considered limitations.
While our study reflects an average population in our relapse clinic, factors such as relapse frequency, regional and seasonal variation in Vitamin D limit the generalisability of our results across this population and across regions, so we have considered our results in the context of the relevant literature when designing our clinical algorithm.
Conclusion
Our study supports recent evidence that bone loss begins early in MS and illustrates that predicting BMD in this group is difficult. Bone loss is likely to increase with disease progression so it is necessary to identify those at risk of fractures early, treat appropriately and continue to monitor over the long-term. The algorithm proposed here should aid clinicians in early identification and management of patients at risk of fractures. While the algorithm has been designed considering our patient group (patients in an acute relapse clinic), we feel it could be applied in any similar clinical setting i.e. patients with RRMS on disease modifying medications, which could be the focus of further work. 
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